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Dear Editor,  
Luteolin (3,4,5,7-tetrahydroxyflavone) is a naturally found flavone, which is obtained 
from numerous plant species (Kim and Kim, 2012). Chemically, it has a C6-C3-C6 structure 
that contains two benzene rings and one oxygen-containing ring with a C2-C3 carbon double 
bond. Structure-activity studies (SAS) have revealed that the presence of hydroxyl moieties at 
carbons 5, 7, 3 and 4 positions of the luteolin structure and the presence of the 2–3 double 
bond are accountable for its numerous pharmacological activities (Lin et al., 2008). Luteolin 
is naturally found as a glycosylated form, is existing in several types of fruits and vegetables, 
such as pepper, thyme, broccoli, and celery (Lopez-Lazaro, 2009). Various research studies 
have confirmed that luteolin possesses antioxidant, anticancer, anti-inflammatory, and neuro-
protective effects; though, a coherent review of the scientific literature related to its neuropro-
tective effects is still lacking.  
In this letter, conclusive evidences have been presented for the potent antioxidant activity 
of luteolin reported in various in vitro and in vivo studies (Table 1). Luteolin also reduces in-
flammation in brain tissues and in regulating different cell signaling pathways (Dirscherl et 
al., 2010). Oxidative stress and neuro-inflammation are possible drivers of neurodegeneration. 
Thus, a chemical moiety like luteolin with potential antioxidant and anti-inflammatory activi-
ty could be used as a therapeutic agent for neurodegenerative diseases.   
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Table 1: Recent updates on neuropharmacological effects of luteolin 
Key Findings References 
Luteolin induces apoptosis of numerous types of cancerous cells. It induces 
apoptosis by activating ER stress and mitochondrial dysfunction in glioblastoma 
cell lines and in vivo, which delivers the anti-cancer agent to treat glioblastoma. 
(Wang et al., 2017) 
Luteolin assists as a potential interference for neurodegenerative diseases relat-
ed to oxidative stress. Luteolin demonstrated to decrease H2O2- or xan-
thine/xanthine oxidase-induced oxidative damage and generation of intracellular 
reactive oxygen species (ROS). 
(Kim et al., 2017) 
Luteolin serves as a potential therapeutic agent for protection of blood-brain bar-
rier (BBB) by preventing inflammation following fAβ1-40-induced injury. 
(Zhang et al., 2017) 
Luteolin showed an inhibitory effect on the course of kindling and related oxida-
tive stress and henceforth might be a potential molecule in the epilepsy treat-
ment. 
(Tambe et al., 2017) 
Luteolin has negative modulatory effects on both recombinant and endogenous 
GABAARs and prevents phasic rather than tonic inhibition in the hippocampus. 
(Shen et al., 2016) 
Luteolin suggestively upgraded the spatial learning and memory weakening in-
duced by treatment of streptozotocin. Streptozotocin expressively decreased the 
CA1 pyramidal layer thickness and luteolin treatment entirely stopped the inhibi-
tory effect of streptozotocin. 
(Wang et al., 2016) 
Pretreatment with luteolin repressed seizure initiation, length, and severity fol-
lowing injection of pentylenetetrazole, reversed cognitive impairment, decreased 
neuronal and oxidative stress impairment, and increased phosphoactivation of 
PKA and CREB as well as BDNF expression. 
(Zhen et al., 2016) 
By addition of luteolin as a dietary supplement, it inhibited the activity of brain 
microglia during aging and activation by LPS in adults. Hence, luteolin inhibits 
neuroinflammation and improves cognition in the healthy aged animal.  
(Burton et al., 2016) 
Luteolin protects Alzheimer's disease rats against Aβ-induced cognitive impair-
ment via regulating the cholinergic system as well as preventing oxidative inju-
ries. Consequences suggesting that luteolin have potential as a therapy for Alz-
heimer's disease. 
(Yu et al., 2015) 
Luteolin has an ability to reduce expression of the IL-1 receptor, and treatment 
with IL-1 receptor antagonist inhibited IL-1β/luteolin-induced expression of COX-
2, which activates anti-survival and anti-inflammatory mechanisms that contrib-
ute to the chemopreventive activity of this diet-derived molecule. 
(Lamy et al., 2015) 
The chronic dose of luteolin expressively down-regulated the BACE1 and NF-κB 
expression as well as accompanied by weakening the Aβ deposition. This 
suggests a potential therapeutic use of luteolin for cerebral hypo perfusion linked 
cognitive dysfunction in Alzheimer's disease. 
(Fu et al., 2014) 
Luteolin and quercetin can be direct inhibitors of monoamine oxidase-A in nerve 
cells by targeting mitochondria. 
(Bandaruk et al., 
2014) 
Luteolin protects mice brain from traumatic brain injury by preventing inflamma-
tory response, as well as luteolin-induced autophagy may perform an essential 
role in its neuroprotection. 
(Xu et al., 2014a) 
Luteolin and apigenin protect the dopaminergic neurons possibly by decreasing 
oxidative damage, neuroinflammation along with activation of microglia as well 
as improved neurotrophic potential. 
(Patil et al., 2014) 
Luteolin has a positive effect on neuroinflammatory events in neurodegenerative 
diseases by MAPK, NF-κB, and Akt pathways suppression in activated microglial 
cells. 
(Zhu et al., 2014) 
Luteolin prevents methamphetamine-induced hyperactivity and behavioural sen-
sitization in mice through the ERK1/2/∆FosB pathway. 
 
(Yan et al., 2014) 
Luteolin suggestively induces growth inhibition of SH-SY5Y tumor cells by induc-
ing apoptosis accompanied by G0/G1 cell cycle growth arrest and connected 
loss in mitochondrial membrane potential. As such, luteolin can be established 
as a potent anticancer molecule against brain tumor disorders. 
(Wang et al., 2015) 
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Key Findings References 
Luteolin suggestively ameliorated secondary brain injuries induced by traumatic 
brain injury, such as neurological deficits, brain water content, and neuronal 
apoptosis. 
(Xu et al., 2014b) 
Orally administered luteolin protects mice brain from sodium nitroprusside-
induced oxidative damage through scavenging and chelating effects. 
(Nazari et al., 2013) 
Treatment with luteolin recovers the scopolamine-induced reduction in cell pro-
liferation and neuroblast differentiation in the dentate gyrus. The amelioration of 
scopolamine-induced amnesia by luteolin is associated with the increase in 
brain-derived neurotrophic factor, acetylcholine, as well as a reduction in lipid 
peroxidation. 
(Yoo et al., 2013) 
Long-term oral administration of luteolin enhanced neuronal injury and cognitive 
performance through decreasing oxidative stress and ChE activity in diabetic 
rats, which shows that luteolin, might be a potential therapeutic agent for the 
treatment and/or prevention of diabetic encephalopathy. 
(Liu et al., 2013) 
Luteolin protects the brain from ischemic damage, and this outcome might be via 
reduction of oxidative stress and apoptosis, as well as upregulation of the clau-
din-5 expressions. 
(Qiao et al., 2012a) 
Luteolin protects the brain from the damage caused by permanent middle cere-
bral artery occlusion (pMCAO), and this outcome might be through downregula-
tion of NF-κB, p38MAPK, TLR4, TLR5, as well as upregulation of expression of 
ERK. 
(Qiao et al., 2012b) 
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